156 related articles for article (PubMed ID: 26718726)
1. Improved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center.
Lange SE; Liu J; Adkins DR; Powell MA; Van Tine BA; Mutch DG
Gynecol Oncol; 2016 Feb; 140(2):307-12. PubMed ID: 26718726
[TBL] [Abstract][Full Text] [Related]
2. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
[TBL] [Abstract][Full Text] [Related]
3. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Hensley ML; Miller A; O'Malley DM; Mannel RS; Behbakht K; Bakkum-Gamez JN; Michael H
J Clin Oncol; 2015 Apr; 33(10):1180-5. PubMed ID: 25713428
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and survival outcomes of women with uterine leiomyosarcoma: A Turkish Uterine Sarcoma Group Study-003.
Ayhan A; Gungorduk K; Khatib G; Fırat Cüylan Z; Boran N; Gökçü M; Çelik H; Özgül N; Akbayir Ö; Şimşek T; Bakay A; Faruk Köse M; Tunç M; Küçükgöz Güleç Ü; Koç S; Kuşçu E; Vardar MA; Akilli H; Taskiran C; Mutlu Meydanlı M
Curr Probl Cancer; 2021 Oct; 45(5):100712. PubMed ID: 33685725
[TBL] [Abstract][Full Text] [Related]
6. Uterine leiomyosarcoma: an updated series.
Rauh-Hain JA; Oduyebo T; Diver EJ; Guseh SH; George S; Muto MG; del Carmen MG
Int J Gynecol Cancer; 2013 Jul; 23(6):1036-43. PubMed ID: 23714705
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
Hyman DM; Sill MW; Lankes HA; Piekarz R; Shahin MS; Ridgway MR; Backes F; Tenney ME; Mathews CA; Hoffman JS; Aghajanian C; Hensley ML
Gynecol Oncol; 2017 Jan; 144(1):96-100. PubMed ID: 28094040
[TBL] [Abstract][Full Text] [Related]
8. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
9. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
Iasonos A; Keung EZ; Zivanovic O; Mancari R; Peiretti M; Nucci M; George S; Colombo N; Carinelli S; Hensley ML; Raut CP
Cancer; 2013 May; 119(10):1816-22. PubMed ID: 23456762
[TBL] [Abstract][Full Text] [Related]
10. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
Hensley ML; Wathen JK; Maki RG; Araujo DM; Sutton G; Priebat DA; George S; Soslow RA; Baker LH
Cancer; 2013 Apr; 119(8):1555-61. PubMed ID: 23335221
[TBL] [Abstract][Full Text] [Related]
12. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
Ben-Ami E; Barysauskas CM; Solomon S; Tahlil K; Malley R; Hohos M; Polson K; Loucks M; Severgnini M; Patel T; Cunningham A; Rodig SJ; Hodi FS; Morgan JA; Merriam P; Wagner AJ; Shapiro GI; George S
Cancer; 2017 Sep; 123(17):3285-3290. PubMed ID: 28440953
[TBL] [Abstract][Full Text] [Related]
14. Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.
Arend RC; Toboni MD; Montgomery AM; Burger RA; Olawaiye AB; Monk BJ; Herzog TJ
Oncologist; 2018 Dec; 23(12):1533-1545. PubMed ID: 30139839
[TBL] [Abstract][Full Text] [Related]
15. Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment.
An Y; Wang S; Li S; Zhang L; Wang D; Wang H; Zhu S; Zhu W; Li Y; Chen W; Ji S; Guo X
BMC Cancer; 2017 Sep; 17(1):639. PubMed ID: 28893210
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.
Chantharasamee J; Wong K; Potivongsajarn P; Qorbani A; Motamed N; Brackert S; Cohen J; Chmielowski B; Kalbasi A; Rao J; Nelson S; Singh A
Cancer Med; 2022 Aug; 11(15):2906-2912. PubMed ID: 35307963
[TBL] [Abstract][Full Text] [Related]
18. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
19. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.
Raut CP; Nucci MR; Wang Q; Manola J; Bertagnolli MM; Demetri GD; Morgan JA; Muto MG; Fletcher CD; George S
Eur J Cancer; 2009 Nov; 45(16):2818-24. PubMed ID: 19647426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
